Viking Therapeutics Inc (VKTX : NASDAQ)
Common Stock
$40.85
USD
+10.74 (35.67%)
Last updated: 2026-09-22
Follow VKTX
VKTX
Viking Therapeutics Inc
WealthAwesomePerformance
1 Day
+35.67%
1 Week
+36.39%
1 Month
+20.54%
YTD
+34.86%
Key Statistics
Market Cap
$3.51B
52W High
$43.15
52W Low
$24.88
P/E Ratio
-
50 Day MA
$33.78
200 Day MA
$33.28
Beta
0.68
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/22/2026 | $37.00 | $41.73 | $36.34 | $40.85 | $40.85 | 41,227,642 |
| 9/21/2026 | $29.57 | $30.70 | $28.41 | $30.11 | $30.11 | 5,023,476 |
| 9/18/2026 | $29.57 | $29.68 | $28.40 | $28.99 | $28.99 | 2,665,300 |
| 9/17/2026 | $30.24 | $30.54 | $29.26 | $29.36 | $29.36 | 2,082,703 |
| 9/16/2026 | $30.02 | $30.77 | $28.80 | $29.52 | $29.52 | 2,994,045 |
| 9/15/2026 | $31.21 | $31.25 | $29.70 | $29.95 | $29.95 | 2,807,988 |
| 9/14/2026 | $31.70 | $32.43 | $31.39 | $31.53 | $31.53 | 1,849,102 |
| 9/11/2026 | $32.26 | $33.05 | $31.70 | $31.98 | $31.98 | 2,207,193 |
| 9/10/2026 | $32.50 | $32.65 | $31.87 | $32.13 | $32.13 | 1,711,000 |
| 9/9/2026 | $33.36 | $34.60 | $32.59 | $32.70 | $32.70 | 2,032,000 |
Analyst Price Targets
Based on 19 analysts covering VKTX · as of Sep 17, 2026
Wall Street analysts forecast VKTX stock price to rise 126.2% over the next 12 months.
Consensus
Buy4.42 / 5.00
Avg. Target
US$92.39
+126.2% Upside
Current Price
US$40.85
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VKTX's historical volatility
30-Day Vol
99.9%
Annualized
90-Day Vol
79.6%
Annualized
Trend (90d)
+29.9%
Annualized drift
90d Mean
US$45.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$42.33 | US$29.99 – US$59.76 |
| 60 trading days | US$43.87 | US$26.94 – US$71.44 |
| 90 trading days | US$45.46 | US$25.02 – US$82.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -88.85%
- EPS (Diluted)
- -4.67
- Book Value
- 3.50
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About VKTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| LHSW | Lianhe Sowell International Group Ltd Ordinary Shares | $0.89 | +105.33% |
| KFIIR | K&F Growth Acquisition Corp. II Rights | $0.09 | +73.36% |
| ZEO | Zeo Energy Corp. | $0.49 | +57.04% |
| RAIN | Rain Enhancement Technologies Holdco, Inc. Class A Common Stock | $1.02 | +54.31% |
| NBRGR | Newbridge Acquisition Limited Rights | $0.36 | +53.19% |
| GRML | Greenland Mines Ltd | $14.15 | +50.21% |
| CWD | CaliberCos Inc. Class A Common Stock | $0.73 | +40.33% |
| FLNA | Filana Therapeutics, Inc. | $1.03 | +39.28% |